Novo makes a rare disease push | Evaluate
Novo Nordisk prepares phase III trial of potential blockbuster drug — MedWatch
ISTH 2022 – Novo moves forward with its Hemlibra rival | Evaluate
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
A multiple ascending dose study of Mim8 in patients with severe haemophilia A with or without factor VIII inhibitors
Novo Nordisk outlines strategy for revamped rare diseases unit | BioWorld
Mim8 Well-tolerated in Early Study, Paving Way for Phase 3 Hem A Trials | Hemophilia A Clinical Trials for Mim8 Supported by Early Results | Hemophilia News Today
Mim8 does not affect FVIII function in hemophilia A - ISTH Congress Abstracts
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Novo Nordisk's Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A
Hemophilia Clinical Research Trials | CenterWatch
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors - ISTH Congress Abstracts
Novo's attempt to snatch Roche's hemophilia crown gets serious
The Effect of rFVIIa and Mim8 Combination in Hemophilia A-like Blood - ISTH Congress Abstracts
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
